Abstract
The recovery (%) of the left ventricular developed pressure by (S)-(-)-pyrapyridolol (5 x 10(-8) M) (90.7%), an optical isomer of a new 5-HT1A receptor antagonist, was greater than that by (R)-(+)-pyrapyridolol (66.2%, control: 34.4%) against ischemia-reperfusion injury in perfused Langendorff guinea-pig hearts. In the perfused mitochondrial preparation, (S)-(-)-pyrapyridolol inhibited the mitochondrial Ca2+ (Cam) elevation that was brought about by the change of Ca2+ content or pH of perfusate, similar to findings with cyclosporin A, well known to be an inhibitor of the mitochondrial permeability transition pore (MPTP). The mitochondrial K(ATP) channel opener, diazoxide, also inhibited the Cam elevation, but the mitochondrial K(ATP) channel antagonist, 5-hydroxydecanoic acid, attenuated it. There were significantly fewer numbers of TUNEL-positive cells in these (S)-(-)-pyrapyridolol-treated hearts than the control or (R)-(+)-pyrapyridolol, with decreases of the caspase-3 activity. Therefore, these results suggest that (S)-(-)-pyrapyridolol likely inhibits the opening of the MPTP by preventing the Cam overload induced apoptosis related to endogenous 5-HT accumulation in ischemia-reperfusion hearts.
References
Oct 1, 1989·Circulation Research·M Tani, J R Neely
Jul 1, 1989·Circulation·P M Vanhoutte, H Shimokawa
Dec 1, 1984·The American Journal of Cardiology·J T WillersonL M Buja
Mar 19, 1981·The New England Journal of Medicine·P D HirshJ T Willerson
May 1, 1996·The Journal of Experimental Medicine·L Casciola-RosenA Rosen
Feb 10, 1998·Journal of Cardiovascular Pharmacology·Y HottaJ Sakakibara
Apr 29, 1998·Annual Review of Physiology·G KroemerM Resche-Rigon
Sep 30, 1998·Cell·D R Green
Jun 22, 1999·European Journal of Pharmacology·T NilssonL Edvinsson
Oct 8, 1999·European Journal of Pharmacology·Y HottaM Kohno
Apr 11, 2000·Cell Calcium·E J GriffithsH S Silverman
Oct 24, 2000·Japanese Journal of Pharmacology·S V YimJ H Chung
Feb 24, 2001·Journal of Cardiovascular Pharmacology·Y HottaK Matsui
Nov 10, 2001·Circulation Research·H IshidaT Sato
Mar 16, 2002·Blood·Adamantios SerafeimJohn Gordon
May 10, 2002·Journal of Cardiovascular Pharmacology and Therapeutics·David BrasilNaranjan S Dhalla
Aug 6, 2002·Cardiovascular Research·Derek J HausenloyDerek M Yellon
Jul 11, 2003·Annals of the New York Academy of Sciences·Sergey O BachurinSergey O Sablin
Dec 9, 2003·Cardiovascular Research·Derek J HausenloyDerek M Yellon
Apr 7, 2004·Circulation·Derek HausenloyDerek Yellon
Oct 22, 2004·European Journal of Pharmacology·Yoshihiro HottaNaohito Ohashi
Citations
Apr 9, 2010·Clinical and Experimental Pharmacology & Physiology·Chong-Feng BaiMing-Gao Zhao
Dec 12, 2012·BMC Neuroscience·Misako HaratoShoshiro Okada
Mar 5, 2011·Biological & Pharmaceutical Bulletin·Kumiko Mitsui-SaitohYoshiaki Takaya
May 3, 2014·Biological & Pharmaceutical Bulletin·Tatsuya MutoYoshihiro Hotta
Mar 13, 2010·Clinical and Experimental Nephrology·Yuko SatoNaohisa Ishikawa
Dec 19, 2006·Life Sciences·Masaya HiraiNorihisa Kawamura
Jun 28, 2007·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Sabzali Javadov, Morris Karmazyn